Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SPC 069

X
Drug Profile

SPC 069

Alternative Names: Hypochlorous acid - SpectrumX; SPC-069; SPX-001 - SpectrumX

Latest Information Update: 11 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SpectrumX Medical
  • Developer Innsbruck Medical University; Spectrum Antimicrobials; SpectrumX; SpectrumX Medical
  • Class Anti-inflammatories; Antibacterials; Antifungals; Antivirals; Chlorine compounds; Eye disorder therapies; Noncarboxylic acids; Oxides; Reactive oxygen species; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical COVID 2019 infections; Respiratory tract infections

Most Recent Events

  • 20 Jun 2023 SpectrumX plans a phase I trial in Healthy volunteers in United Kingdom (Inhalation)
  • 24 Nov 2022 SpectrumX plans to submit a Clinical Trial Application (CTA) to the UK MHRA in December 2022
  • 20 Sep 2022 SpectrumX plans a scientific advice meeting with the UK Medicines and Healthcare products Regulatory Agency (MHRA) in November 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top